Search results for covid-19

Although at least one clinical trial of an investigational vaccine is currently underway (https://www.niaid.nih.gov/news-events/nih-clinical-trial-investigational-vaccine-covid-19-begins), the release of such a vaccine could take months or even years.

“The authors of the current study isolated SARS-CoV-2 from nasopharyngeal (roof of the mouth) samples taken from a patient in Sweden who tested positive for COVID-19. Then they infected cultured cells with the isolated virus with or without the presence of hrsACE2.”

“Most breakthrough cases resulted in mild symptoms such as upper respiratory congestion, muscle aches, fever, and loss of taste and smell. While most symptoms resolved after six weeks, 19 percent of breakthrough cases were “long COVID-19” cases with prolonged symptoms.”

“These data demonstrate that antibodies generated by exposure to the poliovirus vaccine are effective in reducing SARS-CoV-2 replication, providing a safe, inexpensive, and widely-available alternative to SARS-CoV-2-specific vaccines. Link to full publication. Watch physician Dr. Roger Sehuelt discuss the different types of COVID-19 vaccinations in this clip with Dr. Rhonda Patrick.”

“The mice that received sulforaphane also exhibited less lung inflammation, one of the hallmarks of COVID-19 and a driver of poor disease outcomes. These findings demonstrate that sulforaphane may be beneficial for preventing or treating COVID-19 while modulating inflammation that typically accompanies the illness.”

“SARS-CoV-2 belongs to the betacoronavirus genus of coronaviruses, which includes SARS-CoV-1, MERS-CoV, and two other human coronaviruses (HCoV-OC43 and HCoV-HKU1), which are responsible for some forms of the “common cold.” The betacoronaviruses can induce immune responses against one another.”

“SARS-CoV-2, the virus that causes COVID-19, elicits a wide range of effects on the human body, many of which are sex-specific. For example, males and females are equally likely to become infected with SARS-CoV-2, but men are more likely to experience worse outcomes and death, regardless of age.”

“None of the infants manifested clinical signs of COVID-19, such as respiratory or gastrointestinal problems, but two had mild rashes at birth. One of the infants developed breathing problems but responded to non-invasive mechanical ventilation.”

“For example, some people with COVID-19 experience headaches, nausea, vomiting, or "brain fog" – indicators of neurological involvement. Evidence from a 2020 study suggests that SARS-CoV-2, the virus that causes COVID-19, disrupts the blood-brain barrier.”